Phenylephrine bitartrate
This article was originally published in The Tan Sheet
Executive Summary
The final monograph (FM) for over-the-counter nasal decongestant drug products will include phenylephrine bitartrate (PEB) individually and in combination drug products in an effervescent dosage form, FDA states in a final rule published in the Federal Register Aug. 1. Additionally, FDA is "expanding" the definition of the term "effervescent tablet" that appeared in the proposed rule with the new term "effervescent dosage form." The agency is making the change "to provide greater formulation flexibility to permit other effervescent dosage forms to be marketed....the pharmacokinetic data provided for the PEB effervescent tablet dosage form would also support use of an effervescent granule or powder dosage form," the notice states. The agency also concludes phenylephrine hydrochloride and PEB can be used interchangeably due to similar safety and efficacy profiles. FDA proposed the monograph amendment in November 2004 (1"The Tan Sheet" Nov. 8, 2004, p. 11). Alka-Seltzer marketer Bayer submitted comments supporting the amendment to the monograph in February 2005 (2"The Tan Sheet" Feb. 14, 2005, p. 7)...
You may also be interested in...
Decongestant Monograph Definition Expansion Requested By Bayer
FDA should revise its definition of effervescent cold products containing phenylephrine bitartrate (PEB) to make it more flexible, Bayer states in recent comments to FDA
Bayer Bubbles Over Proposed Cough/Cold Monograph Amendment
FDA is proposing to amend the over-the-counter nasal decongestant drugs monograph to include phenylephrine bitartrate (PEB) in effervescent tablets, according to an announcement published in the Federal Register Nov. 2
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”